Bausch Health Companies Inc.
BHC · XNYSCIK 885590fmd_055NGRR59YH94ZXSBB1KZY896KManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2026, 71 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 9,674 | 8,724 | 8,380 | 8,601 | 8,027 | 8,434 | 8,124 | 8,757 | 9,625 | 10,266 |
| Cost of revenue | 2,572 | 2,506 | – | – | – | – | – | – | – | – |
| Gross profit | 7,102 | 6,218 | – | – | – | – | – | – | – | – |
| Realized investment gains (losses) | 0 | – | – | – | – | – | – | – | – | – |
| Research and development | 421 | 361 | 413 | 471 | 452 | 465 | 529 | 604 | 616 | 629 |
| Selling, general and administrative | 2,810 | 2,582 | 2,473 | 2,554 | 2,367 | 2,624 | 2,625 | 2,917 | 3,296 | 3,438 |
| Operating income | (566) | 102 | (2,384) | (203) | 676 | 450 | 454 | 963 | 1,546 | 1,813 |
| Interest expense | 1,836 | 1,840 | 1,685 | 1,612 | 1,534 | 1,426 | 1,464 | 1,328 | 1,388 | 1,604 |
| Interest and investment income | 8 | 12 | 11 | 12 | 13 | 7 | 14 | 26 | 33 | 48 |
| Other non-operating income (expense) | (73) | 348 | 20 | (1,426) | (502) | (373) | (35) | (28) | (247) | (142) |
| Income before taxes | (2,435) | (1,741) | (4,154) | (1,837) | (934) | (1,024) | (129) | (390) | 167 | 367 |
| Income tax expense | (27) | (4,145) | (10) | (54) | (375) | (87) | 83 | 221 | 239 | 247 |
| Net income from continuing operations | (2,408) | 2,404 | (4,144) | (1,783) | (559) | (937) | (212) | (611) | (72) | 120 |
| Net income | (2,408) | 2,404 | (4,144) | (1,788) | (560) | (948) | (225) | (592) | (46) | 157 |
| Net income to common shareholders | (2,409) | 2,404 | (4,148) | (1,788) | (560) | – | – | – | – | – |